Target intelligence / Profile preview

Tripartite motif containing 11 (TRIM11)

Target
TRIM11
Molecular classification
E3 ubiquitin-protein ligase, Tripartite motif family protein, Protein quality control factor
01

Overview

Tripartite motif containing 11 (TRIM11) is a protein characterized by a RING domain, two B-box domains, and a coiled-coil region, consistent with TRIM family structure[1][3][6]. It acts mainly as an E3 ubiquitin ligase regulating clearance of misfolded or aggregated proteins via the ubiquitin-proteasome system (UPS), as well as protein quality control mechanisms in the cytoplasm and nucleus[2][3][4][5]. TRIM11 also modulates SUMOylation and the degradation of key regulatory proteins such as olfactory neurogenic transcription factor PAX6. It has prominent roles in neurogenesis, cancer cell proliferation, protein aggregation diseases, and the innate immune response[2][3][5][7]. Abnormal TRIM11 expression is associated with oncogenesis and neurodegenerative disorders, positioning it as a therapeutic interest in these diseases. TRIM11 does not have any currently approved drugs targeting its activity, but its role in fundamental cellular processes and disease makes it a focus for ongoing research interventions.

Other names
TRIM11Tripartite motif-containing protein 11
02

Mechanism of action

Promotion of misfolded protein degradation via the ubiquitin-proteasome system (UPS); Inhibition of pathogenic protein aggregation and proteostasis restoration; Suppression of viral gene expression (antiviral function); Regulation of transcription factor degradation (e.g., PAX6); SUMOylation-dependent protein removal; Autophagy-dependent degradation of AIM2 inflammasome

03

Biological functions

Ubiquitination of misfolded proteinsRegulation of proteasome activityProtein quality control (PQC)NeurogenesisOncogenesis (cancer development)Innate immune responseSUMOylation
04

Disease associations

Cancer (breast, lung, colon, ovarian)Neurodegenerative diseases (e.g., Parkinson’s disease, Huntington’s disease, spinocerebellar ataxia type 1)Genetic disorders (Congenital central hypoventilation syndrome, limb-girdle muscular dystrophy)Infection/antiviral responsesInflammation (regulation of inflammasome)
05

Safety considerations

Overexpression may contribute to tumorigenesis and poor prognosis in multiple cancersSystemic modulation may affect proteostasis broadly, potentially impacting normal cellular protein turnover and functionSpecific safety concerns are uncharacterized due to lack of TRIM11-targeted drugs
06

Biomarkers

No validated TRIM11-specific biomarkers for patient selection or monitoring are listedExpression changes in cancers and neurodegenerative diseases may serve as investigational biomarkers

Beyond the preview

Go deeper on Tripartite motif containing 11 (TRIM11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tripartite motif containing 11 (TRIM11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call